Carl P. Sherr & Co. LLC Sells 823 Shares of Johnson & Johnson (NYSE:JNJ)

Carl P. Sherr & Co. LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,016 shares of the company’s stock after selling 823 shares during the quarter. Johnson & Johnson comprises about 0.8% of Carl P. Sherr & Co. LLC’s portfolio, making the stock its 28th largest holding. Carl P. Sherr & Co. LLC’s holdings in Johnson & Johnson were worth $1,593,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. IFS Advisors LLC boosted its holdings in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC purchased a new stake in shares of Johnson & Johnson in the third quarter worth about $31,000. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson during the fourth quarter valued at approximately $32,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson in the 3rd quarter worth approximately $35,000. Finally, Activest Wealth Management purchased a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $40,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Citigroup cut their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Barclays boosted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Wolfe Research began coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target for the company. Wells Fargo & Company reduced their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Finally, Bank of America lowered their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 1.5 %

Shares of JNJ opened at $166.13 on Wednesday. The firm has a fifty day moving average price of $149.72 and a 200-day moving average price of $155.92. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $399.98 billion, a P/E ratio of 24.98, a P/E/G ratio of 2.56 and a beta of 0.52. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.29 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 2.99%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.